200
Participants
Start Date
August 31, 2006
Primary Completion Date
March 31, 2013
Study Completion Date
March 31, 2013
Synvisc (Hylan G-F20; hyaluronan injection)
1 ml of hyaluronan (Synvisc) injected once a week for 2 consecutive weeks
Bupivicaine (local anesthesia injection)
1 ml of bupivicaine 0.5% injected once a week for 2 weeks
Kenalog (triamcinolone; corticosteroid injection)
1 ml (40mg) of triamcinolone (Kenalog) injected the first week, followed by a placebo injection of 1 ml 0.5% bupivacaine the second week; Kenalog is a non-suspension steroid preparation and is less likely to cause post-injection flares than a suspension preparation
Hospital for Special Surgery, New York
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
NIH
Genzyme, a Sanofi Company
INDUSTRY
Hospital for Special Surgery, New York
OTHER